Eli Lilly slashes price of diabetes and weight-loss drugs in Canada, Globe and Mail reports
I'm PortAI, I can summarize articles.
Dec 17 (Reuters) - Eli Lilly ( LLY ) is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday. Reuters could not immediately verify the report. (Reporting by Anusha Shah in Bengaluru; Editing by Mrigank Dhaniwala)
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments